These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18300304)

  • 1. Physical stabilization of Norwalk virus-like particles.
    Kissmann J; Ausar SF; Foubert TR; Brock J; Switzer MH; Detzi EJ; Vedvick TS; Middaugh CR
    J Pharm Sci; 2008 Oct; 97(10):4208-18. PubMed ID: 18300304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature.
    Ausar SF; Foubert TR; Hudson MH; Vedvick TS; Middaugh CR
    J Biol Chem; 2006 Jul; 281(28):19478-88. PubMed ID: 16675449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers.
    Kissmann J; Joshi SB; Haynes JR; Dokken L; Richardson C; Middaugh CR
    J Pharm Sci; 2011 Feb; 100(2):634-45. PubMed ID: 20669328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unusual self-assembly properties of Norovirus Newbury2 virus-like particles.
    Tresset G; Decouche V; Bryche JF; Charpilienne A; Le Cœur C; Barbier C; Squires G; Zeghal M; Poncet D; Bressanelli S
    Arch Biochem Biophys; 2013 Sep; 537(1):144-52. PubMed ID: 23871846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
    Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
    Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
    Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particle formulation optimization by miniaturized high-throughput screening.
    Mohr J; Chuan YP; Wu Y; Lua LH; Middelberg AP
    Methods; 2013 May; 60(3):248-56. PubMed ID: 23639868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.
    Kramer RM; Zeng Y; Sahni N; Kueltzo LA; Schwartz RM; Srivastava IK; Crane L; Joshi SB; Volkin DB; Middaugh CR
    J Pharm Sci; 2013 Dec; 102(12):4305-14. PubMed ID: 24129946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallization and X-ray analysis of 23 nm virus-like particles from Norovirus Chiba strain.
    Hasegawa K; Someya Y; Shigematsu H; Kimura-Someya T; Nuemket N; Kumasaka T
    Acta Crystallogr F Struct Biol Commun; 2017 Oct; 73(Pt 10):568-573. PubMed ID: 28994405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.
    Hutson AM; Atmar RL; Marcus DM; Estes MK
    J Virol; 2003 Jan; 77(1):405-15. PubMed ID: 12477845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adsorption and aggregation properties of norovirus GI and GII virus-like particles demonstrate differing responses to solution chemistry.
    da Silva AK; Kavanagh OV; Estes MK; Elimelech M
    Environ Sci Technol; 2011 Jan; 45(2):520-6. PubMed ID: 21121659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles.
    Hu L; Trefethen JM; Zeng Y; Yee L; Ohtake S; Lechuga-Ballesteros D; Warfield KL; Aman MJ; Shulenin S; Unfer R; Enterlein SG; Truong-Le V; Volkin DB; Joshi SB; Middaugh CR
    J Pharm Sci; 2011 Dec; 100(12):5156-73. PubMed ID: 21858822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of norovirus removal performance in a coagulation-rapid sand filtration process by using recombinant norovirus VLPs.
    Shirasaki N; Matsushita T; Matsui Y; Oshiba A; Ohno K
    Water Res; 2010 Mar; 44(5):1307-16. PubMed ID: 19922975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants.
    Shi L; Sanyal G; Ni A; Luo Z; Doshna S; Wang B; Graham TL; Wang N; Volkin DB
    J Pharm Sci; 2005 Jul; 94(7):1538-51. PubMed ID: 15929070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of novel vaccines based on virus-like particles or chimeric virions.
    Bárcena J; Blanco E
    Subcell Biochem; 2013; 68():631-65. PubMed ID: 23737067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.
    Ball JM; Graham DY; Opekun AR; Gilger MA; Guerrero RA; Estes MK
    Gastroenterology; 1999 Jul; 117(1):40-8. PubMed ID: 10381908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of recombinant norwalk virus particles with the 105-kilodalton cellular binding protein, a candidate receptor molecule for virus attachment.
    Tamura M; Natori K; Kobayashi M; Miyamura T; Takeda N
    J Virol; 2000 Dec; 74(24):11589-97. PubMed ID: 11090157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts.
    Xia M; Farkas T; Jiang X
    J Med Virol; 2007 Jan; 79(1):74-83. PubMed ID: 17133551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.
    LoBue AD; Lindesmith L; Yount B; Harrington PR; Thompson JM; Johnston RE; Moe CL; Baric RS
    Vaccine; 2006 Jun; 24(24):5220-34. PubMed ID: 16650512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.